Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy…

NCT00454779 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00454779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00454779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy…
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2007
Completion date
January 1, 2014
Enrollment
113 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or recurrent squamous cell carcinoma of head and neck